
If you are a frequent RxTrace reader, you might have notice that I haven’t
been writing for a while. No, I haven’t been sick with Covid-19 (not yet
anyway) or sick with anything else. No, I didn’t run for elective office in
the recent general election. Any other theories? In reality, I intended to
take the month of March off as a well-deserved vacation, and I did that.
Then, when Covid-19 hit, there wasn’t much to write about, mainly because of the uncertainty. After that, I got busy with house remodeling projects and consulting. And now I am announcing my retirement from most (maybe not all) consulting, and from RxTrace.

Drug manufacturers facing the November 27, 2017 deadline for applying unique identifiers to their products should take care when interpreting the FDA’s recent draft compliance policy. All the headlines scream (including last week’s RxTrace essay: “



